TP508 TFA

立即咨询

TP508 TFA

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

包装与价格：

包装	价格(元)
5mg	电议
10mg	电议
50mg	电议
100mg	电议
200mg	电议

产品介绍

TP508 TFA 是一种 23 个氨基酸的非蛋白水解凝血酶肽，代表凝血酶分子受体结合结构域的一部分。TP508 TFA 可激活内皮NO synthase (eNOS)并刺激人内皮细胞中 NO 的产生。TP508 TFA 通过激活内皮细胞和干细胞以使血管再生和组织再生。

生物活性

TP508 TFA is a 23-amino acid nonproteolyticthrombinpeptide that represents a portion of the receptor-binding domain ofthrombinmolecule. TP508 TFA activates endothelialNO synthase(eNOS)and stimulates production of NO in human endothelial cells. TP508 TFA activates endothelial cells and stem cells to revascularize and regenerate tissues^[1]^[2].

体外研究
(In Vitro)

TP508 (50 μg/mL; 24 hours; HCAEC) treatment reverses radiation-induced endothelial dysfunction (ED) and loss of NO signaling by attenuating the downregulation of eNOS expression. TP508 treatment is able to stimulate NO production in the irradiated cells^[1].
TP508 mitigates effects of nuclear radiation on human endothelial cells in culture restoring endothelial NO production, tube formation and accelerating repair of radiation-induced DNA double-strand breaks (DSB)^[1].
TP508 acts as an antagonist for the effects of thrombin. TP508 peptide inhibits these thrombin-induced effects through a RGD and αvβ3-related mechanism^[3].

Western Blot Analysis^[1]

Cell Line:	Primary human coronary artery endothelial cells (HCAEC)
Concentration:	50 μg/mL
Incubation Time:	24 hours
Result:	Prevented the radiation-induced downregulation of eNOS.

体内研究
(In Vivo)

TP508 (10 mg/kg; intravenous injection; male CD-1 mice) treatment mitigates radiation-induced endothelial cell damage, also significantly increases survival of CD-1 mice when injected 24 h after 8.5 Gy exposure^[1].

Animal Model:	Male CD-1 mice (12-15-week old) with γ irradiation^[1]
Dosage:	10 mg/kg
Administration:	Intravenous injection
Result:	Mitigated radiation-induced endothelial cell damage, also significantly increased survival of CD-1 mice.

Clinical Trial

分子量

2426.46

性状

Solid

Formula

C₉₉H₁₄₇N₂₈F₃O₃₈S

Sequence

Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val

Sequence Shortening

AGYKPDEGKRGDACEGDSGGPFV

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据

In Vitro:

H₂O : 50 mg/mL(20.61 mM;Need ultrasonic)

配制储备液

浓度溶剂体积质量

1 mg

5 mg

10 mg

1 mM	0.4121 mL	2.0606 mL	4.1212 mL
5 mM	0.0824 mL	0.4121 mL	0.8242 mL
10 mM	0.0412 mL	0.2061 mL	0.4121 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.
请依序添加每种溶剂： PBS
Solubility: 100 mg/mL (41.21 mM); Clear solution; Need ultrasonic

*以上所有助溶剂都可在本网站选购。